Cardinal Health Inc. (CAH)
Cardinal Health: Precision Medicine Drives A Sustained Revenue Growth Path
Cardinal Health is rated Buy, driven by robust growth in its Pharmaceutical and Specialty Solutions segment and precision medicine exposure. PSS revenues reached $234.8 billion in FY2026, up 15% YoY, accounting for 92% of CAH's total revenues, with further growth expected from gene therapy and Solaris Health. Precision medicine, growing at a projected 17% CAGR, positions the company to capture a substantial share of an underserved market, supporting long-term top-line expansion.
Here's Why Cardinal Health (CAH) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
3 Reasons Growth Investors Will Love Cardinal (CAH)
Cardinal (CAH) possesses solid growth attributes, which could help it handily outperform the market.
Cardinal Health Stock Hits a Record High After Earnings: Is CAH Still a Buy?
Cardinal Health (CAH) gave investors plenty to like in its fiscal fourth-quarter report this week, sending shares to a record high of $258 as Wall Street digests another earnings beat and an encouraging FY27 outlook.
CAH Q4 Earnings Call Centers on Fiscal 2027 Growth Outlook
Cardinal Health targets 13%-15% fiscal 2027 EPS growth as pharma demand normalizes and specialty, At-Home and buybacks remain key priorities for execution.
CAH Q4 Earnings Beat on Pharma Strength, Revenues Miss, Stock Up
Cardinal Health beats fiscal Q4 EPS estimates as profit surges, while revenues miss; fiscal 2027 guidance points to continued earnings growth.
Cardinal Health Q4 Earnings Call Highlights
Cardinal Health NYSE: CAH reported fourth-quarter fiscal 2026 results marked by growth in revenue, operating earnings and adjusted earnings per share, supported by demand in its pharmaceutical and specialty businesses and a one-time tariff-related benefit in its medical products segment.
Existing Home Sales Data in Focus
Pre-market futures are correcting Monday's slight selloff at this hour; ultimately, as we had said in this space yesterday, we don't expect much movement either direction until inflation reports begin to hit the tape Wednesday morning with the Consumer Price Index (CPI) Inflation Rate. The Dow is +71 points presently, the S&P 500 +16 and the Nasdaq +129 points.
Small Biz Index, Existing Home Sales & More Earnings
We don't expect much movement either direction until inflation reports begin to hit the tape Wednesday morning.
Compared to Estimates, Cardinal (CAH) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for Cardinal (CAH) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Cardinal Health (CAH) Q4 Earnings Beat Estimates
Cardinal Health (CAH) came out with quarterly earnings of $2.91 per share, beating the Zacks Consensus Estimate of $2.42 per share. This compares to earnings of $2.08 per share a year ago.
Cardinal Health forecasts full-year profit above estimates on specialty drug strength
U.S. drug distributor Cardinal Health on Tuesday forecast fiscal 2027 profit well above Wall Street expectations after topping fourth-quarter profit estimates, driven by sustained demand for specialty drugs.
